Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.

The company said an NCI trial and a China study remain ongoing despite a Phase III study in relapsed/refractory disease failing, with an unusually long OS result in the control arm.

A China green light for domestic firm Avistone's c-Met inhibitor was based on positive outcomes from the Phase II/III FUGEN study in Chinese patients with recurrent relapsing glioma with the rare PTPRZ1-MET fusion gene. Avistone’s overseas partner Apollomics is also studying the molecule in a Phase II program outside China.

The US FDA approved Day One’s pediatric brain cancer drug Ojemda, ImmunityBio’s bladder cancer immunotherapy Anktiva, an uncomplicated UTI claim for Utility Therapeutics’ Pivya, which has a long history in Europe, and Pfizer’s hemophilia B gene therapy Beqvez.